NNC 61-0029 ((-)DRF2725):: The single dose pharmacokinetics of a novel dual acting PPARα and PPARγ agonist in Caucasian and Japanese healthy subjects

被引：0
|
作者：
Skrumsager, BK
Nielsen, KK
Reinhardt, R
Pedersen, PC
机构：
来源：
DIABETES | 2001年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A445 / A445
页数：1
相关论文
共 11 条
  • [1] NNC 61-0029 ((-)DRF2725):: The multiple dose pharmacokinetics of a novel dual acting PPARα and PPARγ agonist in healthy subjects and type 2 diabetic patients
    Skrumsager, BK
    Nielsen, KK
    Pedersen, PC
    DIABETES, 2001, 50 : A131 - A132
  • [2] Ragaglitazar (NNC 61-0029, (-)DRF 2725):: The efficacy and safety of a novel dual PPARα and PPARγ agonist in patients with type 2 diabetes
    Strand, J
    Sandeman, D
    Skovsted, B
    Edsberg, B
    Müller, P
    DIABETES, 2002, 51 : A144 - A145
  • [3] Pharmacokinetics of single doses of the novel PPAR α/γ dual agonist muraglitazar (BMS-298585) in healthy human subjects
    Swaminathan, A
    Frost, CE
    Raymond, R
    Reeves, R
    Mosqueda-Garcia, R
    DIABETES, 2004, 53 : A147 - A147
  • [4] Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects
    Patel, Maulik R.
    Kansagra, Kevinkumar A.
    Parikh, Devang P.
    Parmar, Deven V.
    Patel, Hardik B.
    Soni, Mayur M.
    Patil, Uday S.
    Patel, Harilal V.
    Patel, Jaimik A.
    Gujarathi, Swagat S.
    Parmar, Krupi V.
    Srinivas, Nuggehally R.
    CLINICAL DRUG INVESTIGATION, 2018, 38 (01) : 57 - 65
  • [5] Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects
    Maulik R. Patel
    Kevinkumar A. Kansagra
    Devang P. Parikh
    Deven V. Parmar
    Hardik B. Patel
    Mayur M. Soni
    Uday S. Patil
    Harilal V. Patel
    Jaimik A. Patel
    Swagat S. Gujarathi
    Krupi V. Parmar
    Nuggehally R. Srinivas
    Clinical Drug Investigation, 2018, 38 : 57 - 65
  • [6] Safety, tolerability and pharmacokinetics of E3030, a novel PPAR alpha/gamma dual agonist, in Japanese healthy male subjects
    Takeuchi, Yutaka
    Nishioka, Yuki
    Kitahara, Yasumi
    Hasegawa, Setsuo
    Ohnishi, Akihiro
    DIABETES, 2006, 55 : A145 - A145
  • [7] Ragaglitazar:: The pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPARα and γ agonist in healthy subjects and patients with type 2 diabetes
    Skrumsager, BK
    Nielsen, KK
    Müller, M
    Pabst, G
    Drake, PG
    Edsberg, B
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (11): : 1244 - 1256
  • [8] Pharmacokinetics and safety of CKD-501, a novel PPAR alpha/gamma dual agonist, after oral administration in healthy female subjects.
    Lee, H. E.
    Kim, J. W.
    Kim, J. R.
    Lim, K. S.
    Kim, B. H.
    Ahn, S. K.
    Kim, C.
    Yu, K. S.
    Shin, S. G.
    Jang, I. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S95 - S95
  • [9] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OSP-7238, a Novel Dipaptidyl Peptidase IV Inhibitor: Single Ascending Dose Study in Healthy Male Caucasian and Japanese Subjects
    Woodruffe-Peacock, Charlotte
    Brearley, Christopher
    Brennan, Kieran
    Lorch, Ulrike
    DIABETES, 2009, 58 : A535 - A536
  • [10] A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects
    Choi, JaeDuk
    Kim, Youngmin
    Eun, Kahee
    Morrow, Linda
    Hompesch, Marcus
    Baek, Seungjae
    JOURNAL OF HEPATOLOGY, 2020, 73 : S455 - S456
12